Articles
13.04.2022
How do you win the race to market? Our top conside...

Introduction Early Access Programs, also known as special access programs, give patients access to m...

Read more
Articles
28.03.2022
Correlating value with price in the US oncology ma...

An affordable and sustainable market access landscape is key to ensure patient access to life-saving...

Read more
Articles
16.03.2022
The impacts of Market Access combination pricing

We explore why combination pricing is an issue in the oncology space and why payers and manufacturer...

Read more
Articles
10.03.2022
Orphan status higher prices in the UK

Beyond the regulatory level, a well-recognised challenge for companies launching drugs in orphan dis...

Read more
Articles
01.03.2022
China's most recent NRDL update

In December 2021, China once again updated its National Reimbursed Drugs List (NRDL).

Read more
Articles
24.02.2022
Patient reported outcomes

This educational blog explores what PROs are, explains why they of growing importance in the digital...

Read more
Articles
07.02.2022
Advanced therapy medicinal product withdrawals

Advanced therapy medicinal products (ATMPs) are medicinal products for human use that are based on l...

Read more
Articles
02.02.2022
Developing a STA/HST submission to NICE

NICE require a broad range of evidence to be included within the reimbursement dossier, including cl...

Read more
Articles
01.02.2022
Changes to NICE's health technology evaluation

This reforms have been welcomed by the industry as they should support faster access to medicines as...

Read more
Articles
27.01.2022
Early access schemes in France

The 2021 Social Security Law made provision for overhauling the early scheme in France. As of 1st Ju...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.